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ABSTRACT
Background: Pancreas surgery has developed into a fairly safe procedure in terms of mortality, but is
still hampered by considerable morbidity. Among the most frequent and dreaded complications are the
development of a post-operative pancreatic fistula (POPF). The prediction and prevention of POPF
remains an area of debate with several questions yet to be firmly addressed with solid answers.
Methods: A systematic review of systematic reviews/meta-analyses and randomized trials in the English
literature (PubMed/MEDLINE, Cochrane library, EMBASE) covering January 2005 to December 2015 on
risk factors and preventive strategies for POPF.
Results: A total of 49 systematic reviews and meta-analyses over the past decade discussed patient,
surgeon, pancreatic disease and intraoperative related factors of POPF. Non-modifiable factors (age,
BMI, comorbidity) and pathology (histotype, gland texture, duct size) that indicates surgery are associ-
ated with POPF risk. Consideration of anastomotic technique and use of somatostatin-analogs may
slightly modify the risk of fistula. Sealant products appear to have no effect. Perioperative bleeding and
transfusion enhance risk, but is modifiable by focus on technique and training. Drains may not prevent
fistulae, but may help in early detection. Early drain-amylase may aid in detection. Predictive scores lack
uniform validation, but may have a role in patient information if reliable pre-operative risk factors can
be obtained.
Conclusions: Development of POPF occurs through several demonstrated risk factors. Anastomotic
technique and use of somatostatin-analogs may slightly decrease risk. Drains may aid in early detection
of leaks, but do not prevent POPF.
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Pancreatic surgery is now performed with better safety and
lower mortality compared to the past.[1,2] Still, post-operative
morbidity remains a challenge and occurs in up to 40–50% of
patient, even in modern series.[3–5] Although complication
patterns after pancreas surgery differ with type and indica-
tion, the most frequent complications reported after a pan-
creatiocoduodenectomy are delayed gastric emptying, post-
operative hemorrhage and post-operative pancreatic fistulas
(POPF). Among these, the most frequent and feared complica-
tion is the development of a POPF.
An international, uniformally agreed-on definition for pan-
creatic fistulae was for a long time not present and thus ham-
pered comparison of both study results as well as the reported
rates from one institution to another.[6] A suggested common
approach has been given by the International Study Group on
Pancreatic Fistulae (ISGPF) in 2005,[7] although different defini-
tions based on drain output of amylase-rich fluid during any
given post-operative time period continue to be used.
POPF is believed to result from growth failure in the pan-
creatic anastomosis with a subsequent leakage of pancreatic
juice and enzymes into the abdomen. A pancreatic leak leads
to prolonged hospitalization, increased morbidity and is even
reported with increased mortality in several series.[8,9] Thus,
treatment and associated clinical course is much dependent
on the severity of the fistula, suggested split into three sever-
ity grades (A–C, see Table 1).[7] Treatment of POPF can be
difficult and management may range from a simple observa-
tion with or without percutaneous drainage, to the urgent
need for reoperation for the management of abdominal sep-
sis with organ failure and prolonged intensive care.
Several studies have looked into predictive patterns of
occurrence, risk features and associated measures to prevent
fistulas. A few recent studies, including conducted meta-anal-
yses, have accumulated updated data. The aim of this review
was to present the current knowledge on risk factors and pre-
ventive strategies for POPF in a collective synopsis.
Methods
We conducted a PubMed/MEDLINE literature search using the
search terms alone and in combination of ‘Post-operative’
AND ‘pancreatic fistula’ OR ‘POPF’ AND ‘pancreas surgery’
AND ‘risk factors’ AND ‘risk scores’. Only studies published
after 2005 were considered to allow for likely reporting
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according to the International Study Group on Pancreatic
Fistula Definition issued that year.[7] The search period ended
as of 3 December 2015 to cover the emerging evidence over
the last decade, since the presentation of the ISGPS definition
in 2005. Specific searches were done for combined key words
with ‘randomized controlled trials’, ‘prospective trials’ and ‘sys-
tematic reviews’, the latter as the topic of POPF has been
investigated in several more specific research questions. The
final inclusion of papers to cite and refer was made at the
discretion of the authors. Where several reports exist, we pri-
oritized the most recent or the one with highest evidence
level. Case reports, single-center retrospective studies and edi-
torials were excluded. Specific management of POPF is a long
and controversial chapter to cover in itself, and as such stud-
ies solely dealing with this aspect of POPF were excluded.
Results
Of a total of 1998 hits in the PubMed literature, we included
49 systematic reviews and meta-analyses,[10–58] all of which
were conducted within the last 5 years (2011–2015). Three of
these were Cochrane reviews.[29,35,36] Further, randomized
clinical trials and trial protocols (for unpublished/ongoing
studies) were identified.[59–76] Additional citations, such as
prospective clinical evaluation, collective reviews or seminal
reports that are influential on the specific concepts were cited
when applicable to the topic discussion.
Based on the identified and updated recent literature, we
first present and discuss risk estimation of POPF based on
surgery and surgical techniques including the type of anasto-
mosis; second, we will discuss pancreas-specific factors includ-
ing texture and the types of underlying pathology; third, we
will discuss biomarkers of risk; further, we will present results
from interventions, including use of drains, stents or products;
finally, we will discuss the available clinical risk scores and
their current role.
Pancreas surgery and POPF
A collective review of all reports using the standard POPF def-
initions found a POPF rate after pancreaticoduodenectomy in
the range of 20–25%, while the fistula rate after distal pan-
createctomy exceeded 30%.[26] However, there is considerable
bias in this as procedure may be strongly related to the type
of underlying pathology. For example, pancreatic neuroendo-
crine tumors (PNETs) had a higher risk of POPF,[77] but this
was largely attributed to the fact that these types of tumors
more frequently underwent atypical resections and enuclea-
tions,[77,78] thus posing a different risk for ductal injury.
Similarly, distal pancreatectomies have higher fistula rates
(25–40%)[79] than formal pancreas resections, such as pancrea-
ticoduodenectomy. In distal resections, tail resections appear to
have higher risk than more central resections,[80] and a sys-
tematic review demonstrated superiority of stapler closure over
suture closure in distal pancreatectomies.[10] However, the
largest RCT on stapler versus hand-sewn closure of the pancre-
atic remnant (the DISPACT trial) found no difference between
the two methods.[61] ‘Wrapping’ techniques using the omen-
tum or falciform ligament to wrap the pancreaticojejunal anas-
tomosis or the pancreatic section of distal pancreatectomy
have not been associated with reduction of fistulas.[23]
Currently, no differences between laparoscopic and open sur-
gery in the incidence of POPF have been demonstrated in dis-
tal resections or pancreaticoduodenectomy for either benign
or malignant disease, but data on oncological outcomes are
insufficient.[16,81,82] A recent small RCT failed to demonstrate
a difference between pancreaticojejunostomy and stapled clos-
ure in distal pancreatectomy.[76]
Anastomotic technique after pancreaticoduodenectomy
The best anastomotic technique in pancreas surgery has been
an area of controversy for a long time and raised consider-
able debate among experts and investigators.[83] Several
recent studies and meta-analyses have reported POPF results
from various variations of surgical anastomotic techni-
ques.[43,47,48,50,65,84,85]. Six meta-analyses [43,45–48,50]
have investigated the effect of the two most commonly per-
formed anastomotic techniques for creating continuity
between the pancreas remnant and the gastrointestinal tract –
pancreaticogastrostomy and pancreaticojejunostomy – and
their effect on fistula rates, and found significantly different
rates of POPF in all six meta-analyses. The difference in the
POPF rates is likely due to the variation in studies included,
yet the risk reduction remains similar across studies (odds
ratio at about 0.51 in favor of pancreaticogastrostomy). The
meta-analyses, although conducted and published within the
same time-frame (five published in 2015, one in 2014) include
different number of trials and patients (ranging from 4 to 8
randomized trials; and from 676 to 1211 patients included),
and also arrive at different conclusions concerning the add-
itional effect on other outcomes, such as biliary fistula rates
and intra-abdominal fluid collections. Despite the slight differ-
ence in included material, the superiority of pancreaticogas-
trostomy appears consistent in all the meta-analyses, as all six
studies conclude with an overall reduced risk for POPF.
Notably, a recent small Canadian RCT found no difference
between the two techniques, and the trial was stopped
early.[85]
Anastomosis between the pancreatic stump and the
jejunum includes various forms ranging from end-to-side
Table 1. Consensus parameters for POPF grading (ISGPS criteria).
Grade A B C
Clinical conditions Well Often well Ill appearing/bad
Specific treatmenta No Yes/no Yes
US/CT (if obtained) Negative Negative/positive Positive
Persistent drainage
(after 3 weeks)b
No Usually yes Yes
Reoperation No No Yes
Death related to POPF No No Possibly yes
Signs of infections No Yes Yes
Sepsis No No Yes
Readmission No Yes/no Yes/no
ISGPS denotes International Study Group of Pancreatic Surgery; US: ultrasonog-
raphy; CT: computed tomographic scan; POPF: post-operative pancreatic fistula.
Reproduced from Bassi et al., Surgery 2005 [7].
aPartial (peripheral) or total parenteral nutrition, antibiotics, enteral nutrition,
somatostatin analog and/or minimal invasive drainage.
bWith or without a drain in situ.
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duct-to-mucosa anastomosis, end-to-side or end-to-end inva-
gination techniques (dunking). The most frequently used
technique for pancreaticojejunostomy is the end-to-side,
duct-to-mucosa anastomosis.
A Chinese RCT [75] showed that an invagination technique
(‘binding pancreaticojejunostomy’) significantly decreased
post-operative complication and pancreaticojejunostomy leak-
age rates (with fistula rates approaching zero) and shortened
hospital stay when compared with conventional pancreatico-
jejunostomy. However, these results were not confirmed in
two French prospective case–control studies.[86,87] Thus, the
role of this technique is not yet confirmed or validated
externally.
The neck of the pancreas is a vascular watershed between
the celiac and superior mesenteric arterial systems. In a pro-
spective, non-randomized study,[88] the blood supply at the
cut surface of the pancreas was evaluated, and if found inad-
equate, the pancreas was cut back 1.5–2.0 cm to improve the
blood supply. The technique resulted in a very low POPF rate.
The co-called ‘Blumgart anastomosis’ using transpancreatic
U-sutures has also been proposed to decrease the leak rate,
and modifications of this technique have achieved a favorable
outcome in some non-randomized trials. Others have investi-
gated the effect of separating the pancreaticojejunostomy
from the biliary anastomosis, but found no significant differ-
ence in fistula rates with single-loop over double-loop
(Roux-en-Y) anastomosis.[17]
Some expert centers perform total pancreatectomy in
highly selected cases to prevent a POPF from a high-risk pan-
creatic anastomosis in patients unlikely to tolerate a severe
leak. In a recent study from Heidelberg in Germany,[89]
around 20% of 434 total pancreatectomies were performed
because of the morphology of the otherwise remaining pan-
creas; athrophic with pre-existing diabetes mellitus, extremely
soft or lipomatous pancreas or a pancreas with inherent pan-
creatitis that would be associated with a presumably
unacceptable high risk of anastomosis-related complications;
or because of high risks of combined arterial resections and
potential POPF. Notably, these are highly selected patients
and represent a situation where the pros and cons of total
pancreatectomy must be carefully discussed with the patient
prior to surgery. While the pertinent information is not easily
obtained pre-operatively, the patient’s frailty (presence of
comorbidity), the impression of the pancreatic gland on imag-
ing studies (atrophic, small duct), the underlying pathology
(benign vs. malign) and the type of procedure planned
(respective procedure) may give some advice to the likeli-
hood that a total pancreatectomy may be considered as an
alternative to a high-risk pancreatic anastomosis.
Pancreatic gland and duct characteristics
Small pancreatic duct (such as3 mm) has been reported to
be an independent risk factor for POPF.[90,91] Gland texture
also represents a potential contributing factor in anastomotic
failures.[92] A ‘soft gland’ is usually associated with higher risk
of POPF, but there is a lack of consensus in how to object-
ively score this feature. The combination of a soft gland and
a small duct increases the risk for fistulae with several magni-
tudes.[93] One study performed ultrasound elastography
intraoperatively in order to quantify the texture of the
gland.[94] Others have suggested pre-operative computed
tomography (CT) calculated pancreatic remnant volume and
duct width to offer useful information about the risk of
POPF.[95] Evaluation of the ‘elastic modulus’ by a mechanical
method ex vivo has been attempted to correlate with the
tactile impression of the operating surgeon.[96] While the
measurements correlated well (but not perfect) with the sur-
geons’ tactile impression of a hard or soft gland, the method
is limited by the ex vivo approach. Currently, the surgeon’s
tactile impression is what determines gland texture. Whether
alternative techniques are warranted to specifically reduce
POPF rates in soft glands with small ducts have yet to be
demonstrated.
Biomarker and alternative detection techniques
Metabolic profiling of predictive biomarkers has also been
attempted.[97] A fluorescent-based chymotrypsin detection
probe was able to detect increased enzyme in pancreatic
fluid, which correlated with development of fistulae.[98]
Validation and generalized availability hampers the daily use
of these promising techniques.
Currently, the use of a low albumin level may be the most
consistent, widespread available and low cost alternative for
prediction of fistula risk.[90,99–101] A study using intraperito-
neal microdialysis [97] to monitor intraperitoneal metabolites
(glycerol, lactate, pyruvate and glucose) close to the pancrea-
ticojejunostomy showed that patients who later developed
clinically significant POPF had higher intraperitoneal glycerol
concentrations and lactate/pyruvate ratios, and lower glucose
concentrations in combination with an increase in trypsino-
gen activation peptide. Also, several different measures of
amylase in either serum or drain fluids have been proposed
to correlate with fistula risk.[102–104]
Stents in pancreatic surgery
Stents to drain the pancreatic duct can be placed externally
or internally after pancreatic surgery. Stents represent another
controversial area for which evidence is conflicting. One sin-
gle-institution series found no protective effect of either
internal or external stent use, and suggested even some
adverse effects to be associated with the placement of
stents.[105] A Cochrane systematic review [36] suggested the
use of stents to be potentially beneficial, but based on few
patients (n¼ 656) and low-level evidence. In another meta-
analysis of four trials comprising 416 patients,[24] the use of
external pancreatic duct stenting was found to reduce the
incidence of both any grade POPF formation [OR 0.37, 95%
confidence interval (CI) 0.23–0.58, p< 0.001] and clinically sig-
nificant (grade B or C) POPF formation (OR 0.50, 95% CI
0.30–0.84, p< 0.001) following pancreaticoduodenectomy.
The use of internal stents in pancreatic ducts anastomosis did
not appear to reduce the rate of POPF in a second meta-
analysis,[52] but the evidence is weak and based on limited
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level 1 evidence. Currently, the jury is still out on this ques-
tion, and the decision to place a stent or not is left to the
surgeon’s discretion.
Post-operative drains
Use of drains to prevent or to assess risk of fistula continues
to be debated.[106–109] A recent RCT was stopped prema-
turely as the no-drain group had an excess mortality com-
pared to the drain group (12% in no-drain compared to 3%
for drains), and has argued that routine non-use of drains
should be avoided.[64] A subsequent meta-analyses [11]
found one RCT and four non-randomized comparative studies
recruiting 1728 patients. Patients without prophylactic drain-
age after pancreaticoduodenectomy had significantly higher
mortality (OR ¼2.32, 95%CI: 1.11–4.85; p¼ 0.02), despite the
fact that they were associated with fewer overall complica-
tions (OR ¼0.62, 95%CI: 0.48–0.82; p¼ 0.00), major complica-
tions (OR ¼0.75, 95%CI: 0.60–0.93; p¼ 0.01) and readmissions
(OR ¼0.77, 95%CI: 0.60–0.98; p¼ 0.04). There were no signifi-
cant differences in the rates of pancreatic fistula, intra-
abdominal abscesses, post-pancreatectomy hemorrhage, bil-
iary fistula, delayed gastric emptying, reoperation or radio-
logic-guided drains between the two groups. Notably, this
meta-analyses is highly skewed toward the trial results from
the van Buren study,[64] questioning the validity of perform-
ing meta-analytic techniques to this question in the first
place. Results from the DRAPA trial may give new clues to
the role and use of drains in pancreatic surgery.[63]
Somatostatin analogs
Use of octreotide after pancreatic surgery remains a contro-
versial topic.[35,110–112] In a Cochrane review [35] covering
21 trials with a total of 2348 patients, there was a reduction
in overall fistula rates with the use of somatostatin-analogs
after pancreas surgery (RR 0.66; 95% CI 0.55–0.79; n¼ 2206).
However, when investigating those trials that specifically
reported clinically relevant fistulae, no difference was found
(RR 0.69; 95% CI 0.38–1.28; n¼ 292). Intra-arterial injection of
octreotide did not affect gland texture in a small RCT.[70]
Pasireotide is a new somatostatin analog used in the treat-
ment of Cushing syndrome, and with a 40-times higher affin-
ity to the somatostatin-5 receptor compared to other
somatostatin-analogs. A recent RCT on pasireotide [113] dem-
onstrated a significant reduction in clinically relevant fistulas,
leaks and abscesses (relative risk, 0.44; 95% CI, 0.24 to 0.78;
p¼ 0.006). The effect remained significant in favor of pasireo-
tide when looking specifically at type of surgery (pancreatico-
duodenectomy vs. distal resections) and duct size (dilated vs.
normal). This drug is currently more costly than other somato-
statin-analogs, for which cost-effectiveness have not been
demonstrated.[114]
Fibrin sealants and duct occlusion techniques
Covering of the anastomosis with a sealant to protect from
leakage is an intuitively attractive approach. However,
evidence is weak and most studies report no beneficial effect
of this approach.[25,115] No effect of TachosilTM was reported
in a randomized trial.[71] Occlusion of the pancreatic duct
with a chemical substance to avoid a pancreatic anastomosis
during pancreaticoduodenectomy has been tried in some
centers. A Dutch/Italian RCT [116] showed that duct occlusion
(Ethibloc, Neoprene or Trasylol) without pancreaticojejunos-
tomy significantly increased the risk of endocrine pancreatic
insufficiency. However, the technique did not reduce post-
operative complications or mortality, and there has been no
widespread use of this method.
Clinical risk scores
Independent risk factors associated with POPF have been pro-
posed in multivariable risk scores for pre-operative risk predic-
tion.[117–121] Common to several scores is that BMI and
pancreatic duct size together are strong predictors of the risk
of POPF. The Fistula Risk Score proposes four variables on a
10-point scale; however, the score can only be evaluated
intraoperatively as it considers the amount of blood loss as
one of the risk factors. In addition gland texture, duct size and
type of pathology (pancreas mass vs. others) are included.[120]
Indeed, intraoperative blood loss appears to be the strongest
factor in this construct.[121] Also, the validation effort of a mul-
ticenter study was weak at best as it essentially compared
results among four surgeons, and thus generalizability has yet
to be proven. An alternative score relied on pathologist assess-
ment of pancreatic fibrosis and fatty infiltration, thus hamper-
ing the pre-operative assessment of risk.[119] Consequently,
only one proposed pre-operative risk score has yet to be exter-
nally validated. This appears simple and easy to use and essen-
tially relies on BMI and duct size alone.[118]
Conclusions
The prediction and prevention of POPF remains an area of
debate. Patient, surgeon and intraoperative factors are all
important in addressing the POPF risk. Non-modifiable factors
such as patients’ age, BMI, comorbidity and the underlying
pathology that indicate surgery may be inherently associated
with risk. Gland texture and duct size are similarly non-modifi-
able, while choice of anastomotic technique and use of som-
atostatin-analogs may reduce the POPF risk. Sealant products
are not effective. Perioperative bleeding and transfusion
increase risk and is object to the surgeons’ meticulous focus
on technique. Drains do not prevent fistulae, but may help in
early detection and appropriate timely intervention.
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